Model-based cost-effectiveness analyses for the treatment of acute stroke events: A review and summary of challenges

Value in Health

Volumn 12, Issue 4, 2009, Pages 507-520

  Earnshaw, Stephanie R ^a,b   Wilson, Michele ^b   Mauskopf, Josephine ^b   Joshi, Ashish V ^c  

^a RTI Health Solutions ^*  (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c NOVO NORDISK INC   (United States)

Author keywords

Cost effectiveness analysis; Decision analysis; Stroke outcomes; Systematic review

Indexed keywords

ANALYTIC METHOD; AUSTRALIA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANADA; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DENMARK; DISEASE MODEL; ECONOMIC ASPECT; ECONOMIC MODEL; HEALTH CARE COST; HUMAN; MATHEMATICAL MODEL; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; REVIEW; STROKE; SWEDEN; SYSTEMATIC REVIEW; UNCERTAINTY; UNITED KINGDOM; UNITED STATES;

ACUTE DISEASE; ASPIRIN; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FIBRINOLYTIC AGENTS; HUMANS; MODELS, ECONOMIC; PLATELET AGGREGATION INHIBITORS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 66249095628     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00467.x     Document Type: Article

References (53)

1. American Heart Association. Heart disease and stroke statistics - update 2008. Available from: http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA. 107.187998 [Accessed February 13, 2008].
2. Asplund K, Stegmayr B, Peltonen M. From the twentieth to the twenty-first century: a public health perspective on stroke. In : Ginsberg MD, Bogousslavsky J, eds. Cerebrovascular Disease Pathophysiology, Diagnosis, and Management, Vol. 2. Malden : Blackwell Science, 1998.
3. Sundberg G, Bagust A, Terent A. A model for costs of stroke services. Health Policy 2003 81 94. (Pubitemid 35418237)
4. Wardlaw JM, Seymour J, Cairns J, et al. Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. Stroke 2004 35 : 2477 83.
5. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 2002 5 : 82 97. (Pubitemid 34274866)
6. Fagan S, Morgenstern L, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998 50 : 883 90.
7. Samsa GP, Matchar DB, Williams GR, et al. Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT). J Eval Clin Pract 2002 8 : 61 70. (Pubitemid 34219552)
8. Samsa GP, Reutter RA, Parmigiani G, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol 1999 52 : 259 71.
9. Matchar DB, Samsa GP, Matthews JR, et al. The Stroke Prevention Policy Model: linking evidence and clinical decisions. Ann Intern Med 1997 127 (Suppl. 8 704 11.
10. Moodie ML, Carter R, Mihalopoulos C, et al. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. Stroke 2004 35 : 1041 56.
11. Mihalopoulos C, Cadilhac DA, Moodie MJ, et al. Development and application of Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS): an Australian economic model for stroke. Int J Technol Assess Health Care 2005 21 : 499 505. (Pubitemid 41642843)
12. Sandercock P, Berge E, Dennis M, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke. Stroke 2004 35 : 1490 8.
13. Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovascular Dis 2005 20 : 193 200. (Pubitemid 41254181)
14. Ehlers L, Andersen G, Clausen LB, et al. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 2007 38 : 85 9.
15. Sinclair SE, Frighetto L, Loewen PS, et al. Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke. Pharmacoeconomics 2001 19 : 927 36.
16. Earnshaw SR, Joshi AV, Wilson MR, et al. Cost-effectiveness of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Stroke 2006 37 : 2751 58.
17. Caro JJ, Huybrechts KF. Stroke Treatment Economic Model (STEM): predicting long-term costs from functional status. Stroke 1999 30 : 2574 29.
18. Stahl JE, Furie KL, Gleason S, et al. Stroke: effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations. Radiology 2003 228 : 659 68.
19. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004 363 : 768 74.
20. National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Eng J Med 1995 333 : 1581 7.
21. Hacke W, Kaste M, Blumki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. NEJM 2008 359 : 1317 29.
22. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005 352 : 777 85.
23. Kase CS. Hemostatic treatment in the early stage of intracerebral hemorrhage: the recombinant factor VIIa experience. Stroke 2005 36 : 2321 2.
24. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London : National Institute for Health and Clinical Excellence, 2004.
25. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada (3rd ed.). Ottawa : Canadian Agency for Drugs and Technologies in Health, 2006.
26. Gold MR, Siebel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York : Oxford University Press, 1996.
27. Gage BF, Candinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996 156 : 1829 36.
28. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998 29 : 1083 91.
29. Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke outcomes. Stroke 1994 25 : 1721 5.
30. Samsa GP, Cohen SJ, Goldstein LB, et al. Knowledge of risk among patients at increased risk for stroke. Stroke 1997 28 : 916 21.
31. Samsa GP, Matchar DB, Goldstein L, et al. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J 1998 136 (4 Pt 1 703 13.
32. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke 2001 32 : 964 71.
33. Hallan S, Asberg A, Indredavik B, et al. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J Intern Med 1999 246 : 309 16.
34. Post P, Stiggelbout A, Wakker P. The utility of health states after stroke: a systematic review of the literature. Stroke 2001 32 : 1425 9.
35. Aoki N, Kitahara T, Fukui T, et al. Management of unruptured intracranial aneurysm in Japan: a Markovian decision analysis with utility measurements based on the Glasgow coma scale. Med Decis Making 1998 18 : 357 64.
36. Mark D, Hlatky M, Califf R, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared to streptokinase for acute myocardial infarction. N Engl J Med 1995 332 : 1418 24.
37. Duncan P, Lai S, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology 2000 39 : 835 41.
38. King J, Glick H, Mason T, et al. Elective surgery for asymptomatic, unruptured intracranial aneurysms: a cost-effectiveness analysis. J Neurosurg 1995 83 : 403 12.
39. EuroQoL Group. EuroQoL: a new facility for measurement of health-related quality of life. Health Policy 1990 16 : 199 208.
40. Badia X, Roset M, Montserrat S, et al. La version Espanola del EuroQoL descripcion y aplicaciones. Med Clin (Barc) 1999 112 (Suppl. 1 S79 86.
41. Leibson CL, Hu T, Brown RD, et al. Utilization of acute care services in the year before and after first stroke: a population-based study. Neurology 1996 46 : 861 9.
42. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996 27 : 1459 66.
43. Dewey HM, Thrift AG, Mihalopoulos C, et al. Lifetime cost of stroke subtypes in Australia. Stroke 2003 34 : 2502 7.
44. Sonnenberg FA, Roberts MS, Tsevat J, et al. Toward a peer review process for medical decision analysis models. Med Care 1994 32 (Suppl. 7 S52 64.
45. Nuijten MJ, Starzewski J. Applications of modeling studies. Pharmacoeconomics 1998 13 : 289 91.
46. Nuijten MJ. The selection of data sources for use in modeling studies. Pharmacoeconomics 1998 13 : 305 16.
47. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000 17 : 501 13.
48. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision-analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000 17 : 461 77.
49. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices #8722. Value Health 2003 6 : 9 17. (Pubitemid 36228345)
50. Mandelblatt J, Fryback D, Weinstein M, et al. Assessing the Effectiveness of Health and Medicine. New York : Oxford University Press, 1996.
51. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988 19 : 604 7.
52. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965 14 : 61 5.
53. Keith RA, Granger CV, Hamilton BB, et al. The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil 1987 1 : 6 18.